Use of anxiolytics and hypnotic drugs during COVID-19 pandemic - the literature review

Upotreba anksiolitika i hipnotika tokom COVID-19 pandemije – pregled literature

  • Tea Trajkovski Univerzitet u Beogradu, Medicinski fakultet; Dr Subotića starijeg 8, 11000 Beograd.
  • Nađa Marić Univerzitet u Beogradu, Medicinski fakultet,;Dr Subotića starijeg 8, 11000 Beogard
DOI: https://doi.org/10.5937/mp73-35916
Ključne reči: Engleski

Sažetak


Anksiolitici i hipnotici su lekovi koji se široko koriste. Glavne psihijatrijske indikacije za benzodijazepine su odvikavanje od alkohola / sedativa-hipnotika i katatonija, dok su kod anksioznih poremećaja ili nesanice indikovani samo kratko, ukoliko je lečenje metodama prvog i drugog izbora bilo neefikasno. Širenje virusa SARS-CoV-2 uticalo je na svakodnevni život, psihološku, socijalnu i ekonomsku stabilnost. Pandemija C-19 je multifaktoriski uticala na mentalno zdravlje ljudi, a direktno i indirektno uticala na promene trendova u propisivanju, upotrebe i zloupotrebe anksiolitika i hipnotika tokom pandemije. U ovom članku biće dat pregled dosadašnje literature o upotrebi anksiolitika i hipnotika kod pacijenata sa infekcijom SARS-CoV-2 sa indikacijama i preporukama za njihovu upotrebu, kao i o učestalosti i razlozima upotrebe i zloupotrebe ovih lekova u opštoj populaciji tokom pandemije. Cilj je podržati racionalnu upotrebu i sprečiti epidemiju zloupotrebe benzodiazepina tokom i nakon pandemije C-19.

Biografija autora

Nađa Marić, Univerzitet u Beogradu, Medicinski fakultet,;Dr Subotića starijeg 8, 11000 Beogard

Naučni savetnik, specijalista psihijatrije i vanredni profesor na Medicinskom fakultetu Univerziteta u Beogradu;
Institut za mentalno zdravlje; Milana Kašanina broj 3,11000 Beograd

Reference


  1. Sternbach LH. The benzodiazepine story. Prog Drug Res. 1978;22:229–66.

  2. Maric N, Kostic M, Samardzic J, Pejovic-Nikolic S, Vukovic O. Preporuke za odgovornu upotrebu benzodijazepina u zastiti dusevnog zdravlja. Beograd: Institut za mentalno zdravlje; 2020.

  3. Guina J, Merrill B. Benzodiazepines I: Upping the care on downers: The evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2):17.

  4. Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155–62.

  5. Votaw V, Geyer R, Rieselbach M, McHugh R. The epidemiology of benzodiazepine misuse: A systematic review. Drug and Alcohol Dependence. 2019;200:95-114.

  6. Center for Drug Evaluation, Research. FDA expands Boxed Warning to improve safe use of benzodiazepine drug [Internet]. Fda.gov. 2020 [cited 2021 Nov 25]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class

  7. Center for Drug Evaluation, Research. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning [Internet]. Fda.gov. 2019 [cited 2021 Nov 25]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or

  8. Hawkins E, Malte C, Imel Z, Saxon A, Kivlahan D. Prevalence and trends of benzodiazepine use among Veterans Affairs patients with posttraumatic stress disorder, 2003–2010. Drug and Alcohol Dependence. 2012;124(1-2):154-161.

  9.  Sansone R, Hruschka J, Vasudevan A, Miller S. Benzodiazepine Exposure and History of Trauma. Psychosomatics. 2003;44(6):523-524.



  1. Jeffrey Guina, Sarah R. Rossetter, Bethany J. Derhodes, Ramzi W. Nahhas, Randon S. Welton. Benzodiazepines for PTSD. Journal of Psychiatric Practice, 2015; 21 (4): 281.

  2. Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: A global challenge with old history, epidemiology and progress so far. Molecules. 2020;26(1):39.

  3. Coronavirus (COVID-19) Dashboard [Internet]. Who.int. [cited 2021 Nov 25]. Available from: https://covid19.who.int/

  4. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4(1):e2035057.

  5. Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MCJ, Rozhnova G. Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study. PLoS Med. 2020;17(7):e1003166.

  6. Marić N P. Mental health and COVID-19 pandemic: The literature review. Med podml. 2021;72(3):78–86.

  7. Yue L, Wang J, Ju M, Zhu Y, Chen L, Shi L, et al. How psychiatrists coordinate treatment for COVID-19: a retrospective study and experience from China. Gen Psychiatr. 2020;33(4):e100272.

  8. Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, et al. Neurocovid: Pharmacological recommendations for delirium associated with COVID-19. Psychosomatics. 2020;61(6):585–96

  9. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–27.

  10. Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24(1):176.

  11. Shah K, Kamrai D, Srinivas S, Veluri N, Chaudhari G, Trivedi C, et al. Benzodiazepine interaction with COVID-19 drugs. Prim Care Companion CNS Disord. 2021;23(6):0–0.

  12. Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. Lopinavir-ritonavir for COVID-19: A living systematic review. Medwave. 2020;20(6):e7967.

  13. Bilbul M, Paparone P, Kim A, Mutalik S, Ernst C. Psychopharmacology of COVID-19. Psychosomatics. 2020;61(5):411-427.

  14. Vila-Corcoles A, Satue-Gracia E, Vila-Rovira A, de Diego-Cabanes C, Forcadell-Peris MJ, Hospital-Guardiola I, et al. COVID19-related and all-cause mortality risk among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection: a population-based cohort stuJune 2020.dy in Southern Catalonia, Spain, March-. BMC Public Health. 2021;21(1):1795.

  15. NHS Camden and Islington, NHS Foundation Trust: COVID-19 and Benzodiazepines; https://www.candi.nhs.uk/sites/default/files/COVID-19%20and%20Benzodiazepines%20-%20CI.pdf



  1. Sanders RD, Godlee A, Fujimori T, Goulding J, Xin G, Salek-Ardakani S, et al. Benzodiazepine augmented γ-amino-butyric acid signaling increases mortality from pneumonia in mice. Crit Care Med. 2013;41(7):1627–36.

  2.  Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68(2):163–70.

  3. Daly M, Sutin AR, Robinson E. Longitudinal changes in mental health and the COVID-19 pandemic: evidence from the UK Household Longitudinal Study. Psychol Med. 2020;1–10.



  1. Winkler P, Formanek T, Mlada K, Kagstrom A, Mohrova Z, Mohr P, et al. Increase in prevalence of current mental disorders in the context of COVID-19: analysis of repeated nationwide cross-sectional surveys. Epidemiol Psychiatr Sci. 2020;29:e173.

  2. Yu C, Boone C, Askarian-Monavvari Y, Brown T. The Trends in Pharmacotherapy for Anxiety, Depression and Insomnia During COVID-19: A North York Area Pilot Study. University of Toronto Medical Journal. 2021; 98(1): 41-46.

  3. Hirschtritt ME, Slama N, Sterling SA, Olfson M, Iturralde E. Psychotropic medication prescribing during the COVID-19 pandemic. Medicine (Baltimore). 2021;100(43):e27664.

  4. Milani SA, Raji MA, Chen L, Kuo Y-F. Trends in the use of benzodiazepines, Z-hypnotics, and serotonergic drugs among US women and men before and during the COVID-19 pandemic. JAMA Netw Open. 2021;4(10):e2131012.

  5. Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100–6.

  6. Almeida M, Shrestha AD, Stojanac D, Miller LJ. The impact of the COVID-19 pandemic on women’s mental health. Arch Womens Ment Health. 2020;23(6):741–8.

  7. Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 Coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020;17(5):1729.

  8. Sarangi A, McMahon T, Gude J. Benzodiazepine misuse: An epidemic within a pandemic. Cureus. 2021;13(6):e15816.

  9. Singh S, Sharma P, Balhara Y. The impact of nationwide alcohol ban during the COVID ‐19 lockdown on alcohol use‐related internet searches and behaviour in India: An infodemiology study. Drug and Alcohol Review. 2020;40(2):196-200.

  10. Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97–106.

  11. Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada. Int J Drug Policy. 2021;93(103237):103237.

  12. Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, et al. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020;75(4):343–54.



  1. de Dios C, Fernandes BS, Whalen K, Bandewar S, Suchting R, Weaver MF, et al. Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2021;229(Pt A):109176.

  2. Jones CM, Guy GP Jr, Board A. Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. Drug Alcohol Depend. 2021;219(108486):108486.

  3. Downs CG, Varisco TJ, Bapat SS, Shen C, Thornton JD. Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications. Res Social Adm Pharm. 2021;17(1):2005–8.

  4. [Internet]. Apps.who.int. 2021 [cited 20 December 2021]. Available from: https://apps.who.int/iris/bitstream/handle/10665/65947/WHO_PSA_96.11.pdf?sequence=1&isAllowed=y

  5. Prescription Drug Monitoring Programs (PDMPs) | Drug Overdose | CDC Injury Center [Internet]. Cdc.gov. 2022 [cited 3 January 2022]. Available from: https://www.cdc.gov/drugoverdose/pdmp/index.html



  1. [Internet]. Rfzo.rs. 2021 [cited 20 December 2021]. Available from: http://rfzo.rs/download/pravilnici/lekovi/A1%20Lista_primena%20od%2015.05.2021..pdf

  2. Divac N, Jašović M, Djukić L, Vujnović M, Babić D, Bajčetić M et al. Benzodiazepines utilization and self-medication as correlates of stress in the population of Serbia. Pharmacoepidemiology and Drug Safety. 2004;13(5):315-322.

Objavljeno
2022/10/19
Broj časopisa
Vol. 73 Br. 3 (2022): Medicinski podmladak
Rubrika
Mini pregledni članak